Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed ...

Zydus Lifesciences announced that it has launch ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) ...

A timely medical intervention in the form of a bone marrow transplant, medically known as hematopoietic stem cell ...

Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection ... hematopoietic stem-cell transplant (HSCT) recipients, and patients receiving ...

MUMBAI, Mar 5: Pharma major, Zydus Lifesciences on Wednesday said that it has launched ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in ...

2 As part of risk group stratification, 9584 patients were included in the high-risk population, which consisted of those with prior HSCT, active viral infection, hepatoxic drug use, and advanced ...

The role of the immune response in allogeneic HSCT involves both the eradication of the disease via the graft-vs.-leukemia (GvL) effect and the development of some of the major complications of the ...

Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone ...

designed to protect patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) from infections, and other oral microbiome therapies in its pipeline. SER-155 is currently in the ...